Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

NORGINE-PEDMARQSI-TGA

More Like This

PR Newswire associated0

Norgine announces Swissmedic approval of PEDMARQSI® for the prevention of cisplatin induced hearing loss in children

PR Newswire associated0

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

ACOUSIA THERAPEUTICS REACHES 50% PATIENT ENROLLMENT MILESTONE IN PHASE 2 PROHEAR STUDY

ACOUSIA ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE 2 PROHEAR STUDY EVALUATING ACOU085 (INN: BIMOKALNER) FOR THE PREVENTION OF CISPLATIN-INDUCED OTOTOXICITY

Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial

PR Newswire associated0

Norgine welcomes TGA registration in Australia of IFINWIL® (eflornithine) for adults and children diagnosed with high-risk neuroblastoma (HRNB)[1]

PR Newswire associated0

Norgine strengthens rare disease portfolio with acquisition of Theravia

PR Newswire associated0

Norgine receives positive CHMP opinion recommending approval of NPJ5008 (dantrolene sodium hemiheptahydrate) for the treatment of malignant hyperthermia